# US 2024/0197829 A1 · Treatment of neuropathic corneal pain with ngf

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197829 A1
- Document ID: US20240197829A1
- Status: Published application
- Kind: A1
- Application number: 18/554,511
- Filed: 2022-04-13
- Published: 2024-06-20
- Earliest claimed: 2021-04-13
- Assignees: Dompé Farmaceutici S.P.A.; Tufts Medical Center, Inc.
- Applicants: Dompé Farmaceutici S.P.A; Tufts Medical Center, Inc.
- Inventors: Pedram HAMRAH; Flavio MANTELLI
- Web page: https://patentgrep.com/patent/US20240197829A1

## CPC

- A61K 38/185: {Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3}
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to methods of treating neuropathic corneal pain (NCP) comprising administration of nerve growth factor (NGF).

## Claims

### Claim at position 1

1-10. (canceled)

### Claim 11

A method of treating neuropathic corneal pain (NCP) in a subject in need thereof, comprising administration of a composition comprising NGF.

### Claim 12 (depends on 11)

The method according to claim 11, wherein the NGF is rhNGF.

### Claim 13 (depends on 11)

The method according to claim 11, wherein the subject is a patient suffering from NCP who responds to treatment with a topical anesthetic and/or who has mild inflammation.

### Claim 14 (depends on 13)

The method according to claim 13, wherein the topical anesthetic is proparacaine.

### Claim 15 (depends on 11)

The method according to claim 11, wherein the subject has a Dendritiform Cell Density (cells/mm2) lower than 75.

### Claim 16 (depends on 15)

The method according to claim 15, wherein the subject has a Dendritiform Cell Density (cells/mm2) lower than 70.

### Claim 17 (depends on 11)

The method according to claim 11, wherein the subject is a patient suffering from peripheral or mixed NCP.

### Claim 18 (depends on 11)

The method according to claim 11, wherein the subject is a patient who does not suffer from dry eye disease (DED) and/or from neurotrophic keratitis (NK).

### Claim 19 (depends on 11)

The method according to claim 11, wherein NGF is administered topically to an ocular surface of the subject, in the form of a pharmaceutical composition for ophthalmic use.

### Claim 20 (depends on 19)

The method according to claim 19, wherein NGF is present in the pharmaceutical composition at concentrations ranging from about 0.0001% to about 0.5% w/v.

### Claim 21 (depends on 20)

The method according to claim 20, wherein NGF is present in the pharmaceutical composition at concentrations ranging from about 0.001% to about 0.1% w/v.

### Claim 22 (depends on 21)

The method according to claim 21, wherein NGF is present in the pharmaceutical composition at a concentration of about 0.002% w/v.

### Claim 23 (depends on 11)

The method according to claim 11, wherein the NGF is administered between 3 and 6 times a day for a period between 4 and 12 weeks.
